Kyntra Bio, Inc. Common Stock (KYNB)

Price$6.71

Value ScoreA

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-31.68%

Price vs S&P 500 (4W)-3.44%

VGM Score58.46

Market Capitalization$27.16M

P/E Ratio (Annual)0.15x

All Metrics

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-64.23%

Cash Flow / Share (Quarterly)$-5.29

Price vs S&P 500 (YTD)-31.73%

Gross Margin (TTM)40.70%

Net Profit Margin (TTM)2199.42%

EPS (TTM)$40.46

10-Day Avg Trading Volume0.01M

EPS Excl Extra (TTM)$40.46

Revenue Growth (5Y)-48.41%

EPS (Annual)$45.38

ROI (Annual)-127.92%

Gross Margin (Annual)91.37%

Net Profit Margin (5Y Avg)432.73%

Cash / Share (Quarterly)$21.55

P/E Basic Excl Extra (TTM)0.17x

Revenue Growth QoQ (YoY)36.47%

P/E Normalized (Annual)0.15x

ROA (Last FY)153.40%

Revenue Growth TTM (YoY)-92.77%

EBITD / Share (TTM)$-12.60

ROE (5Y Avg)-47.66%

Operating Margin (TTM)-690.63%

Cash Flow / Share (Annual)$-1.19

P/B Ratio1.03x

Net Income / Employee (Annual)$5,395,600

EV / Revenue (TTM)1.27x

Net Interest Coverage (TTM)-9.02x

ROA (TTM)120.24%

EPS Incl Extra (Annual)$45.38

Current Ratio (Annual)3.39x

Quick Ratio (Quarterly)3.44x

3-Month Avg Trading Volume0.02M

52-Week Price Return-12.06%

P/E Incl Extra (TTM)0.17x

Revenue / Employee (TTM)$218,800

P/S Ratio (Annual)4.22x

Asset Turnover (Annual)0.05x

52-Week High$12.60

Operating Margin (5Y Avg)-375.53%

EPS Excl Extra (Annual)$45.38

CapEx CAGR (5Y)-60.58%

26-Week Price Return-23.75%

Quick Ratio (Annual)3.23x

13-Week Price Return-2.54%

Total Debt / Equity (Annual)0.08x

Current Ratio (Quarterly)3.61x

Enterprise Value$9.41M

Revenue / Share Growth (5Y)-4.07%

Asset Turnover (TTM)0.05x

Revenue / Employee (Annual)$189,400

Inventory Turnover (Annual)0.16x

Pretax Margin (Annual)-905.19%

Cash / Share (Annual)$21.99

3-Month Return Std Dev40.71%

Gross Margin (5Y Avg)69.60%

Net Income / Employee (TTM)$4,812,200

ROE (Last FY)-138.69%

Net Interest Coverage (Annual)-9.72x

EPS Basic Excl Extra (Annual)$45.38

P/FCF (TTM)1.77x

Receivables Turnover (TTM)2.87x

Total Debt / Equity (Quarterly)0.59x

EPS Incl Extra (TTM)$40.46

Receivables Turnover (Annual)18.48x

ROI (TTM)-256.45%

P/S Ratio (TTM)3.65x

Pretax Margin (5Y Avg)-394.97%

Revenue / Share (Annual)$1.59

Price vs S&P 500 (52W)-36.42%

P/E Ratio (TTM)0.17x

EPS Growth TTM (YoY)3265.69%

Year-to-Date Return-23.58%

5-Day Price Return-2.75%

EPS Normalized (Annual)$45.38

ROA (5Y Avg)-4.30%

Net Profit Margin (Annual)2848.63%

Month-to-Date Return-2.75%

EBITD / Share (Annual)$-12.79

Operating Margin (Annual)-814.88%

LT Debt / Equity (Annual)0.08x

ROI (5Y Avg)-42.66%

P/E Excl Extra (TTM)0.17x

LT Debt / Equity (Quarterly)0.59x

EPS Basic Excl Extra (TTM)$40.46

Inventory Turnover (TTM)1.35x

Pretax Margin (TTM)-761.70%

Price vs S&P 500 (13W)-10.80%

Beta1.04x

P/FCF (Annual)0.35x

Revenue / Share (TTM)$1.84

ROE (TTM)-290.91%

52-Week Low$4.85

vGradeA

gGradeC

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-3.76est. -3.42

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.00

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
KYNBKyntra Bio, Inc. Common Stock	A	C	C	$6.71
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Kyntra Bio Inc is a biopharmaceutical company developing novel therapies for oncology and rare diseases. Its pipeline includes Roxadustat and FG-3246, targeting indications such as lower-risk myelodysplastic syndrome-associated anemia and metastatic castration-resistant prostate cancer.